Targeting Smyd3 by antisense oligonucleotides attenuates liver tumor growth
We investigated whether pharamacological inhibition of Smyd3 by antisense oligonucleotides (ASOs) can influence diethylnitrosamine (DEN)-induced liver cancer development. Our phenotypic analyses, among others, included gene expression profiling. Overall design: C57Bl6 mice received a single intraperitoneal injection of 25 mg/kg diethylnitrosamine at day 14 after birth. Livers were harvested at day 133 (P133) or day 260 (P260) after birth. After P133 the mice received intraperitoneally 50 mg/kg Control ASO or Smyd3-ASO twice a week, until P260, when sacrificed. Total RNAs were prepared by Nucleozol extraction and subjected to 3'Quant-Seq procedure.